Effect of the administration rate on the biological responses to a fixed dose of endotoxin in the anesthetized pig

Shock

Volumn 29, Issue 2, 2008, Pages 173-180

  Lipcsey, Miklós ^a   Larsson, Anders ^a   Eriksson, Mats B ^a   Sjölin, Jan ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Animal model; Cytokines; Endotoxic shock; Pig; Sepsis

Indexed keywords

ATROPINE; CARBON DIOXIDE; CYTOKINE; ENDOTOXIN; HEMOGLOBIN; MORPHINE; OXYGEN; PANCURONIUM BROMIDE; PENTOBARBITAL; TILETAMINE PLUS ZOLAZEPAM; XYLAZINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG INFUSION; ENDOTOXEMIA; FEMALE; HEART LEFT VENTRICLE FUNCTION; HEART WORK; HYPOTENSION; INFLAMMATION; LEUKOCYTE ACTIVATION; LEUKOCYTE COUNT; LUNG COMPLIANCE; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PERFUSION; PH MEASUREMENT; RANDOMIZATION; REVERSE ESCALATING DOSE; TEMPERATURE SENSITIVITY; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT;

ANIMALS; BODY TEMPERATURE; CYTOKINES; ENDOTOXINS; HYPOTENSION; INFLAMMATION; INTERLEUKIN-6; RANDOM ALLOCATION; SHOCK, SEPTIC; SWINE; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 38349106713     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/shk.0b013e318067dfbc     Document Type: Article

References (33)

1. Alexander C, Rietschel ET: Bacterial lipopolysaccharides and innate immunity. J Endotoxin Res 7:167-202, 2001.
2. Pridmore AC, Wyllie DH, Abdillahi F, et al.: A lipopolysaccharide- deficient mutant of Neisseria meningitidis elicits attenuated cytokine release by human macrophages and signals via toll-like receptor (TLR) 2 but not via TLR4/MD2. J Infect Dis 183:89-96, 2001.
3. Ziegler EJ, McCutchan JA, Fierer J, et al.: Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med 307:1225-1230, 1982.
4. Ziegler EJ, Fisher CJ, Sprung CL, et al.: Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N Engl J Med 324:429-436, 1991.
5. Greenman RL, Schein RM, Martin MA, et al.: A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gramnegative sepsis. The XOMA Sepsis Study Group. JAMA 266:1097-1102, 1991.
6. McCloskey RV, Straube RC, Sanders C, Smith SM, Smith CR: Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group. Ann Intern Med 121:1-5, 1994.
7. Angus DC, Birmingham MC, Balk RA, et al.: E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis: a randomized controlled trial. E5 Study Investigators. JAMA 283:1723-1730, 2000.
8. Bengsch S, Boos KS, Nagel D, Seidel D, Inthorn D: Extracorporeal plasma treatment for the removal of endotoxin in patients with sepsis: clinical results of a pilot study. Shock 23:494-500, 2005.
9. Teramoto K, Nakamoto Y, Kunitomo T, et al.: Removal of endotoxin in blood by polymyxin B immobilized polystyrene-derivative fiber. Ther Apher 6:103-108, 2002.
10. Staubach KH, Boehme M, Zimmermann M, Otto V: A new endotoxin adsorption device in Gram-negative sepsis: use of immobilized albumin with the MATISSE adsorber. Transfus Apher Sci 29:93-98, 2003.
11. Suzuki H, Nemoto H, Nakamoto H, et al.: Continuous hemodiafiltration with polymyxin-B immobilized fiber is effective in patients with sepsis syndrome and acute renal failure. Ther Apher 6:234-240, 2002.
12. Vincent JL, Laterre PF, Cohen J, et al.: A pilot-controlled study of a polymyxin B-immobilized hemoperfusion cartridge in patients with severe sepsis secondary to intra-abdominal infection. Shock 23:400-405, 2005.
13. Lipcsey M, Larsson A, Eriksson MB, Sjölin J: Inflammatory, coagulatory and circulatory responses to logarithmic increases in the endotoxin dose in the anaesthetised pig. J Endotoxin Res 12:99-112, 2006.
14. Marshall JC: Lipopolysaccharide: an endotoxin or an exogenous hormone? Clin Infect Dis 41(Suppl 7):S470-S480, 2005.
15. Redl H, Bahrami S, Schlag G, Traber DL: Clinical detection of LPS and animal models of endotoxemia. Immunobiology 187:330-345, 1993.
16. Dodds WJ, Abelseth MK: Criteria for selecting the animal to meet the research need. Lab Anim Sci 30:460-465, 1980.
17. Schmidhammer R, Wassermann E, Germann P, Redl H, Ullrich R: Infusion of increasing doses of endotoxin induces progressive acute lung injury but prevents early pulmonary hypertension in pigs. Shock 25:389-394, 2006.
18. Eriksson M, Larsson A, Lundkvist K, Loof L: Endotoxaemic liver injury in a porcine model-relation to tumour necrosis factor-alpha release and survival. Scand J Infect Dis 30:169-172, 1998.
19. Clark CA, Harman EM: Hemodynamic monitoring: pulmonary artery catheters. In Civetta JM, Taylor RW, Kirby RR, (eds.): Critical Care. 3rd ed. Philadelphia: Lippincott Williams & Wilkins, pp 293-302, 1988.
20. Morrison PR, Meyer MP: Constants for use in body surface area formula: mammals. In Altman PL, Dittmer DS, (eds.): Biology Data Book. Washington, DC: Federation of American Society of Experimental Biology, pp 120-122, 1964.
21. Mathison JC, Ulevitch RJ: The clearance, tissue distribution, and cellular localization of intravenously injected lipopolysaccharide in rabbits. J Immunol 123:2133-2143, 1979.
22. DiLuzio NR, Crafton CG: Influence of altered reticuloendothelial function on vascular clearance and tissue distribution of S. enteritidis endotoxin. Proc Soc Exp Biol Med 132:686-690, 1969.
23. Carey FJ, Braude AI, Zalesky M: Studies with radioactive endotoxin. III. The effect of tolerance on the distribution of radioactivity after intravenous injection of Escherichia coli endotoxin labeled with Cr51. J Clin Invest 37:441-457, 1958.
24. Fan H, Cook JA: Molecular mechanisms of endotoxin tolerance. J Endotoxin Res 10:71-84, 2004.
25. Cross AS: Endotoxin tolerance-current concepts in historical perspective. J Endotoxin Res 8:83-98, 2002.
26. Miyazaki M, Sawada S, Nishide T, Iwanaga K, Morimoto K, Kakemi M: Bioavailability assessment of arginine-vasopressin (AVP) using pharmacokineticpharmacodynamic (PK-PD) modeling in the rat. Biol Pharm Bull 23:87-96, 2000.
27. Bachem A: The modified Fechner-Weber law as a complex law of dose-action. Am J Psychol 69:588-603, 1956.
28. Tracey KJ, Beutler B, Lowry SF, et al.: Shock and tissue injury induced by recombinant human cachectin. Science 234:470-474, 1986.
29. Libert C, Vink A, Coulie P, et al.: Limited involvement of interleukin-6 in the pathogenesis of lethal septic shock as revealed by the effect of monoclonal antibodies against interleukin-6 or its receptor in various murine models. Eur J Immunol 22:2625-2630, 1992.
30. Marshall JC, Walker PM, Foster DM, et al.: Measurement of endotoxin activity in critically ill patients using whole blood neutrophil dependent chemiluminescence. Crit Care 6:342-348, 2002.
31. Martich GD, Boujoukos AJ, Suffredini AF: Response of man to endotoxin. Immunobiology 187:403-416, 1993.
32. Brandtzaeg P, Kierulf P, Gaustad P, et al.: Plasma endotoxin as a predictor of multiple organ failure and death in systemic meningococcal disease. J Infect Dis 159:195-204, 1989.
33. Opal SM: The clinical relevance of endotoxin in human sepsis: a critical analysis. J Endotoxin Res 8:473-476, 2002.